Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 14
2004 10
2005 14
2006 9
2007 6
2008 6
2009 14
2010 19
2011 22
2012 12
2013 18
2014 10
2015 23
2016 17
2017 15
2018 7
2019 11
2020 19
2021 10
2022 13
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
MGMT Status as a Clinical Biomarker in Glioblastoma.
Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. Butler M, et al. Among authors: raffeld m. Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27. Trends Cancer. 2020. PMID: 32348734 Free PMC article. Review.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Wilson WH, et al. Among authors: raffeld m. Blood. 2002 Apr 15;99(8):2685-93. doi: 10.1182/blood.v99.8.2685. Blood. 2002. PMID: 11929754 Free article. Clinical Trial.
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. Among authors: raffeld m. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, El Meskini R, Ohler ZW, Maity TK, Venugopalan A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Panchenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Roper N, et al. Among authors: raffeld m. Cell Rep Med. 2020 Apr 21;1(1):100007. doi: 10.1016/j.xcrm.2020.100007. Cell Rep Med. 2020. PMID: 32483558 Free PMC article. Clinical Trial.
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.
Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, Brat D, Perry A, Solomon D, Eberhart C, Giannini C, Quezado M, Aldape K. Pratt D, et al. Among authors: raffeld m. Acta Neuropathol. 2022 Mar;143(3):403-414. doi: 10.1007/s00401-022-02404-9. Epub 2022 Feb 1. Acta Neuropathol. 2022. PMID: 35103816 Free PMC article.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Kochenderfer JN, et al. Among authors: raffeld m. Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28. Blood. 2010. PMID: 20668228 Free PMC article. Clinical Trial.
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Kochenderfer JN, et al. Among authors: raffeld m. J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25. J Clin Oncol. 2015. PMID: 25154820 Free PMC article. Clinical Trial.
Molecular assessment of clonality in lymphoid neoplasms.
Wang HW, Raffeld M. Wang HW, et al. Among authors: raffeld m. Semin Hematol. 2019 Jan;56(1):37-45. doi: 10.1053/j.seminhematol.2018.05.008. Epub 2018 May 26. Semin Hematol. 2019. PMID: 30573043 Review.
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Abel ML, Takahashi N, Peer C, Redon CE, Nichols S, Vilimas R, Lee MJ, Lee S, Shelat M, Kattappuram R, Sciuto L, Pinkiert D, Graham C, Butcher D, Karim B, Sharma AK, Malin J, Kumar R, Schultz CW, Goyal S, Del Rivero J, Krishnamurthy M, Upadhyay D, Schroeder B, Sissung T, Tyagi M, Kim J, Pommier Y, Aladjem M, Raffeld M, Figg WD, Trepel J, Xi L, Desai P, Thomas A. Abel ML, et al. Among authors: raffeld m. Clin Cancer Res. 2023 Sep 15;29(18):3603-3611. doi: 10.1158/1078-0432.CCR-23-0536. Clin Cancer Res. 2023. PMID: 37227187 Free PMC article.
254 results